Biological Information
Background Information:
The G protein-coupled receptors ETA and ETB are both endothelin receptors whose activation results in the elevation of intracellular-free calcium. ETA is expressed primarily on vascular smooth muscles, mediating vasoconstriction and sodium retention, leading to increased blood pressure. ETB is expressed predominantly on the endothelial surface of vessels, mediating vasodilatation through the production of nitric oxide and prostacyclin. ETA activation has damaging effects on preeclampsia, heart failure, pulmonary hypertension, and kidney natriuresis. Endothelin-receptor antagonists (ERA) can improve exercise capacity, hemodynamics, symptoms, and right ventricle function as an important treatment of hypertension. The selective blockade of ETA blocks only the harmful vasoconstriction effects of ETA but maintains the potential beneficial effects mediated by ETB (vasodilatation and endothelin clearance).
No. of Assays on Panel:
2
Assays on Panel:
Family
GPCR
Name
ETA Human Endothelin GPCR Cell Based Agonist IP1 LeadHunter Assay - TW
Item
311010-0
Protein
ETA
Organism
Human
Assay Sub Type
Cell Based
Family
GPCR
Name
ETA Human Endothelin GPCR Cell Based Antagonist IP1 LeadHunter Assay - TW
Item
311010-1
Protein
ETA
Organism
Human
Assay Sub Type
Cell Based
Family:
GPCR
Sub Family:
Endothelin
Class:
Class A
Protein Name:
ETA
Uniprot Number:
P25101
Protein Aliases:
ET-A|ET-AR
Gene Name:
EDNRA
Gene ID:
1909
Accession Number:
S63938
Organism:
Human
Construct Details:
Recombinant
Cell Type:
Chem-1
Assay Information
Assay Type:
Functional
Assay Sub Type:
Cell Based
Functional Mode:
Agonist & Antagonist
Detection Method:
TR-FRET
Measured Response:
Fluorescence
Testing Information
Procedure Summary:
Human recombinant endothelin ETA receptors expressed in Chem-1 cells are used. Test compound and/or vehicle is incubated with the cells (1.5 x 10^6 /ml) in stimulation buffer of IP1 Tb kit for 30 minutes at 37°C. Test compound-induced increase of fluorescence by 50 percent or more (≥50%) relative to the 1 μM endothelin-1 response indicates possible ETA receptor agonist activity. Test compound-induced inhibition of 1 nM endothelin-1 induced increase of fluorescence response by 50 percent or more (≥50%) indicates receptor antagonist activity.
Incubation:
30 min at 37°C
Control Inhibitor:
BQ-610
Control Activator:
Endothelin-1
Criteria For Significance:
≥ 50% increase in IP-one relative to Endothelin-1 response, ≥ 50% inhibition of Endothelin-1-induced response
Test Concentration / Dose:
Compounds are screened at 10, 3, 1, 0.3, 0.1, 0.03, 0.01 and 0.003 μM
Test Sample Requirements:
75 μl of 10 mM stock or 1 mg (pre-weighed) powder (assuming FW ≦500 and purity 100%)
Minimum Order Quantity:
16
Turnaround Time
Standard:
20 Business Days
Reference Compound Data
Clinical Relevance
Therapeutic Area:
Cardiovascular
Adverse / Beneficial Action:
ETA receptor agonism may cause vasoconstriction, positive inotropy, and facilitate cell proliferation (e.g., smooth muscle, mesangial cells).
Additional Information
Brand:
LeadHunter
Testing Location:
Taiwan - Taipei